Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay Laboratory investigation


Yener U., Avsar T., Akgun E., Seker A., BAYRİ Y., Kilic T.

JOURNAL OF NEUROSURGERY, vol.117, no.4, pp.697-704, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 117 Issue: 4
  • Publication Date: 2012
  • Doi Number: 10.3171/2012.6.jns112263
  • Journal Name: JOURNAL OF NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.697-704
  • Istanbul Technical University Affiliated: No

Abstract

Object. Angiogenesis and the platelet-derived growth factor (PDGF) pathway are active in the pathogenesis of vestibular schwannomas (VSs). The purpose of this study was to test whether imatinib mesylate (Gleevec), a PDGF receptor (PDGFR) blocker, reduces angiogenic capacity in sporadic VS and in VS associated with neurofibromatosis Type 2 (NF2) using a conical angiogenesis assay.